Streamlining Population PK Modeling with Phoenix NLME & Pirana: Bridging Efficiency and Precision in Pharmacometrics [APAC Webinar] Webinar Streamlining Population PK Modeling with Phoenix NLME & Pirana: Bridging Efficiency and Precision in Pharmacometrics [APAC Webinar] 日期:2025 年 5 月 28 日, 星期三时间:10am Japan & Korea, 9am ChinaSolutions: Preclinical, Early clinicalServices: PharmacometricsProducts: Phoenix™…Danielle Pillsbury2025 年 4 月 24 日
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Publication Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…Danielle Pillsbury2025 年 3 月 20 日
Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling Video Certara Phoenix 平台 — 全球最值得信赖的药代动力学/药效学(PK/PD)分析与建模平台 Today's drug candidates are more complex than ever. But with development decisions on the line,…Danielle Pillsbury2025 年 2 月 12 日
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies Publication 针对复发难治性(R/R)骨髓纤维化(MF)及其他髓系或实体瘤恶性肿瘤患者的 Navtemadlin 群体药代动力学与药效学分析 This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…Danielle Pillsbury2025 年 2 月 6 日
Understanding Variability in CAR-T Cell Therapy Kinetics Publication 了解 CAR-T 细胞疗法动力学的变异性 Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…Danielle Pillsbury2025 年 1 月 23 日
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease Publication INTERCEPT-AD:一项针对阿尔茨海默病所致轻度认知障碍或轻度痴呆患者的静脉注射 Sabirnetug 的 I 期研究 The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…Danielle Pillsbury2025 年 1 月 8 日
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation Publication 推动非洲定量药理学的发展 — 从能力建设向创造就业过渡 This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…Danielle Pillsbury2024 年 12 月 9 日
Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women Publication 定量药理学和系统药理学方法在改善和优化孕妇和哺乳期妇女药物治疗方面的最新应用 The article "Recent Applications of Pharmacometrics and Systems Pharmacology Approaches to Improve and Optimize Drug…Danielle Pillsbury2024 年 11 月 18 日
Enhancing Pharmacokinetics Workflows at Charles River Case Study 优化 Charles River 实验室的药代动力学工作流程 PreclinicalPhoenix™ Integral Data Repository Charles River, a global leader in drug development, sought to improve…Danielle Pillsbury2024 年 11 月 13 日
Why Clinical Pharmacology & Pharmacometrics Should Collaborate Blog 临床药理学与定量药理学为何要合作 A symbiosis between a modeler and a trialist is often required to develop a model-informed…Danielle Pillsbury2024 年 11 月 8 日